Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
MLAB · Nasdaq · United States · Industrial Instruments For Measurement, Display, And Control
In shortMESA LABORATORIES INC /CO/ is profitable, generates cash and carries moderate debt, with revenue growing (+3.4% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 7.4% | 41/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 2.7% | 31/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 3.9% | 19/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 4.1% | 27/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.72× | 76/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.36× | 91/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.71× | 66/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 1.73× | 2/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.37 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 15.9% | 84/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 5.90× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 5 | 60/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 15.3% | 54/100 |
| Operating margin volatility | 58.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 4.4% | 41/100 |
|---|---|---|
| EPS growth, 3-year average | 92.4% | 100/100 |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 184 | 219 | 216 | 241 | 249 |
| Cost of revenue | 75 | 85 | 83 | 90 | 91 |
| Gross profit | 109 | 134 | 133 | 151 | 158 |
| Research & development | 16 | 20 | 19 | 20 | 20 |
| Operating income | 4.7 | 3.3 | (272) | 16 | 19 |
| Interest expense | 3.9 | 4.8 | 5.7 | 12 | 11 |
| Pre-tax income | 3.6 | (0.4) | (276) | 6 | 12 |
| Income tax | 1.7 | (1.3) | (21) | 7.9 | 5.3 |
| Net income | 1.9 | 0.9 | (254) | (2) | 6.7 |
| Diluted EPS | $0.35 | $0.17 | −$47.20 | −$0.36 | $1.21 |
| Diluted shares (millions) | 5.3 | 5.4 | 5.4 | 5.4 | 5.6 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
0.37 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 10, 2026